... Food and Drug Administration Elrexfio (Elranatamab-Bcmm), Prescribing Information Revised July 2025 — U.S. Food and Drug Administration FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma — U.S. Food and Drug Administration FDA Grants Accelerated Approval to Elrantamab-Bcmm for Multiple Myeloma — U.S. ...
What Is BCMA-Targeted Immunotherapy? (VIDEO)
... Food and Drug Administration Elrexfio (Elranatamab-Bcmm), Prescribing Information Revised July 2025 — U.S. Food and Drug Administration FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma — U.S. Food and Drug Administration FDA Grants Accelerated Approval to Elrantamab-Bcmm for Multiple Myeloma — U.S. ...
... Food and Drug Administration Highlights of Prescribing Information: Elrexfio — Pfizer Highlights of Prescribing Information: Lynozyfic — Regeneron Pharmaceuticals Highlights of Prescribing Information: Talvey — Janssen Pharmaceutical Companies What Do Clinical Trial Results Mean? ...
... From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey (Talquetamab-Tgvs) for Relapsed or Refractory Multiple Myeloma, and Elrexfio ...
What Is the Life Expectancy With Relapsed/Refractory Myeloma?
... From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey (Talquetamab-Tgvs) for Relapsed or Refractory Multiple Myeloma, and Elrexfio ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
Can Multiple Myeloma Be Cured? Advances in Research and Survival
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... Elranatamab-bcmm (Elrexfio) is another BCMA-directed CD3 T-cell engager. Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. Selinexor (Xpovio) is a nuclear export inhibitor that disrupts how cancer cells function and grow. ...
Relapsed vs. Refractory: What It Means in Multiple Myeloma
... Elranatamab-bcmm (Elrexfio) is another BCMA-directed CD3 T-cell engager. Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. Selinexor (Xpovio) is a nuclear export inhibitor that disrupts how cancer cells function and grow. ...
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
Myeloma Treatment Journey: From First Line to Fourth Line
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
... refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey) and elranatamab-bcmm (Elrexfio ...
Multiple Myeloma – An Overview
... refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey) and elranatamab-bcmm (Elrexfio ...
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
8 Refractory Myeloma Therapies: Know Your Treatment Options
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... Elranatamab-bcmm, sold under the brand name Elrexfio, is a BCMA bispecific antibody approved by the FDA in August 2023.7. CAR T-Cell TherapiesTwo BCMA-targeted antibodies are used in a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which involves teaching the immune system’s T cells to attack myeloma cells. ...
Myeloma Relapse Rates and 9 Treatment Options for Relapses
... Elranatamab-bcmm, sold under the brand name Elrexfio, is a BCMA bispecific antibody approved by the FDA in August 2023.7. CAR T-Cell TherapiesTwo BCMA-targeted antibodies are used in a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which involves teaching the immune system’s T cells to attack myeloma cells. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Myeloma Treatments: Risks and Benefits
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Join
